Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Red blood cell deformability is a biophysical property reflecting the ability of erythrocytes to change their shape in response to mechanical forces as they traverse the microcirculation, enabling passage through capillaries smaller than themselves and supporting efficient oxygen transport. This property is determined by the interplay of membrane flexibility, cytoskeletal structure, cytoplasmic viscosity, and hydration status. Loss of RBC deformability occurs in various diseases (including sickle cell disease, hemolytic anemias, diabetes, and neurodegenerative conditions), during blood storage, and with aging, leading to impaired circulation and tissue hypoxia. Several clinical and experimental strategies exist to measure and quantify this property, and its assessment is increasingly used as a biomarker for systemic disease, transfusion efficacy, well as biological aging.
Drugs affecting RBC deformability may improve cytoskeletal or membrane stability, shift cell hydration or oxidative state, or reduce hemoglobin polymerization (in sickle cell disease).
1 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Red blood cell deformability (RBC deformability).